A New Era in Early Cervical Cancer: Sentinel Node Biopsy Alone Is Enough!
In this article
In early-stage cervical cancer , pelvic lymph node status has long been assessed using pelvic lymph node dissection (PLND) . However, PLND can increase lymphedema, lymphocele, nerve damage and persistent pain . Sentinel lymph node biopsy (SLNB) removes only the sentinel nodes, potentially maintaining oncological safety without being inferior while reducing complications .
Published on 15 October 2025 in NEJM , PHENIX is the first large, adequately powered randomized trial with long follow-up directly comparing SLNB and PLND in a non-inferiority design. The findings could influence practice and guidelines.
Who Is Eligible?
This approach can be safely used in early-stage cervical cancer confined to the area around the uterus.
- FIGO 2009 Stages: IA1 (with lymphovascular invasion), IA2, IB1 and IIA1
- All patients undergo intraoperative sentinel lymph node biopsy (SLNB) .
- If sentinel nodes show no cancer on frozen section, patients enter two groups:
- SLNB alone (SLNB-only)
- Additional pelvic lymphadenectomy (SLNB + PLND)
- All patients undergo hysterectomy (uterus removal) and, if needed, adjuvant treatment under a shared protocol.
📊 PHENIX at a Glance
Study Design and Pathway
PHENIXwas a multicenter randomized Phase 3 trial across 18 Chinese centers, using a non-inferiority design to establish that sentinel lymph node biopsy alone (SLNB) produced outcomes not clinically meaningfully worse than pelvic lymphadenectomy (PLND) in the comparator group . This was the study's objective.
🔍 Randomization and Surgical Pathway
- Mapping & SLNB: ICG/blue dye identifies sentinel nodes during surgery, which are removed.
- Frozen Section: If sentinel nodes are frozen-section negative , randomization follows.
- 1:1 Assignment:
- SLNB-only (sentinel biopsy alone)
- SLNB + PLND (additional pelvic lymphadenectomy)
- Hysterectomy: Standard hysterectomy in both arms.
📋 Postoperative Adjuvant Management
Under a uniform protocol at all centers, pathological risk factors guided radiotherapy/chemoradiotherapy or observation .
⚖️ Non-Inferiority Margin
The primary endpoint was 3-year disease-free survival (DFS) . SLNB was considered non-inferior provided the upper confidence limit did not exceed 5%, establishing non-inferiority to PLND .
👥 Sample and Follow-Up
- Total: 838 patients: SLNB-only 420, SLNB + PLND 418.
- Median Follow-Up: 62.8 months.
📊 Main PHENIX Findings
For the primary endpoint (3Y DFS), SLNB was non-inferior ; safety outcomes favored SLNB.
| Outcome | SLNB | PLND | Difference / HR (95% CI) |
|---|---|---|---|
| 3Y DFS | 96.9% | 94.6% | −2.3 points (−5.0 – 0.5); P<0.001 (non-inferiority) |
| Cancer-Specific Survival | 99.2% | 97.8% | HR 0.37 (0.15–0.95) |
| Retroperitoneal Nodal Recurrence | 0 | 9 (2.2%) | — |
| Lymphocele | 8.3% | 22.0% | P<0.001 |
| Lymphedema | 5.2% | 19.1% | P<0.001 |
| Paresthesia | 4.0% | 8.4% | P=0.009 |
| Pain | 2.6% | 7.9% | P=0.001 |
Note: The prespecified upper limit for non-inferiority was 5% .
💬 Interpretation and Clinical Implications
- Oncological Equivalence: SLNB was non-inferior to PLND for 3Y DFS, without adverse cancer-specific survival findings.
- Less Morbidity: Lymphedema, lymphocele, paresthesia and pain were substantially less common with SLNB.
- No Nodal Recurrence: In the SLNB arm, retroperitoneal nodal recurrence was not reported.
- Clinical Proposition: In sentinel-negative early disease, SLNB-only reduces complications while maintaining oncological safety.
Potential Guideline Impact and Future Directions
PHENIX provides strong evidence in sentinel-negative early cervical cancer questioning routine PLND . Guidelines may increasingly state that SLNB alone may be sufficient .
Future studies will clarify mapping failure, micrometastasis management and long-term quality of life, further standardizing practice.
🔗 Source
Tu H, Huang H, Li Y, Chen X, Wang C, Zheng M, Zhang Y, et al. for the PHENIX Investigators.
Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.
N Engl J Med. 2025;393:1463–1474. DOI: 10.1056/NEJMoa2506267
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.